



**HAL**  
open science

## Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance

Johnny Zakhour, Sara F Haddad, Anthony Kerbage, Wertheim Heiman, Pierre Tattevin, Andreas Voss, Serhat Ünal, Abdoul-Salam Ouedraogo, Souha S. Kanj

### ► To cite this version:

Johnny Zakhour, Sara F Haddad, Anthony Kerbage, Wertheim Heiman, Pierre Tattevin, et al.. Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. *International Journal of Antimicrobial Agents*, 2023, 62 (1), pp.106816. 10.1016/j.ijantimicag.2023.106816 . hal-04089149

**HAL Id: hal-04089149**

**<https://hal.science/hal-04089149>**

Submitted on 31 May 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance



Johnny Zakhour<sup>a</sup>, Sara F Haddad<sup>b</sup>, Anthony Kerbage<sup>c</sup>, Heiman Wertheim<sup>d</sup>, Pierre Tattevin<sup>e</sup>, Andreas Voss<sup>f</sup>, Serhat Ünal<sup>g</sup>, Abdoul Salam Ouedraogo<sup>h</sup>, Souha S Kanj<sup>a,\*</sup>, on behalf of the International Society of Antimicrobial Chemotherapy (ISAC) and the Alliance for the Prudent Use of Antibiotics (APUA)

<sup>a</sup> Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

<sup>b</sup> Division of Infectious Diseases, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA

<sup>c</sup> Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

<sup>d</sup> Department of Medical Microbiology and Radboudumc Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands

<sup>e</sup> Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France

<sup>f</sup> Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands

<sup>g</sup> Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

<sup>h</sup> Bacteriology and virology department, Sourou Sanou University Hospital, Burkina Faso

### ARTICLE INFO

#### Article history:

Received 27 December 2022

Accepted 7 April 2023

Editor: Dr Gabriel Levy Hara

#### Keywords:

Diagnostic stewardship

Novel diagnostics in Infectious Diseases

Antimicrobial stewardship

Multidisciplinary teams

Antimicrobial resistance

### ABSTRACT

Antimicrobial resistance (AMR) has been exacerbated by the inappropriate use of diagnostics, leading to excessive prescription of antimicrobials, and is an imminent threat to global health. Diagnostic stewardship (DS) is an auxiliary to antimicrobial stewardship (AMS) and comprises ordering the right tests, for the right patient, at the right time. It also promotes the judicious use of rapid and novel molecular diagnostic tools to enable the initiation of proper antibiotic therapy, while avoiding excessive use of broad-spectrum antibiotics. Proper interpretation of test results is crucial to avoid overdiagnosis and excessive healthcare costs. Although many rapid diagnostic tools have been developed with a high diagnostic yield, they are often limited by accessibility, cost, and lack of knowledge regarding their use. Careful consideration of clinical signs and symptoms with knowledge of the local epidemiology are essential for DS. This enables appropriate interpretation of microbiological results. Multidisciplinary teams that include well trained professionals should cooperate to promote DS. Challenges and barriers to the implementation of DS are mostly caused by scarcity of resources and lack of trained personnel and, most importantly, lack of knowledge. The lack of resources is often due to absence of awareness of the impact that good medical microbiology diagnostic facilities and expertise can have on the proper use of antibiotics.

© 2023 The Authors. Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

### 1. Introduction

Antimicrobial stewardship (AMS) programs have been developed worldwide to help curtail the pandemic of antimicrobial

resistance (AMR). The goal of these programs is to ensure that patients receive timely and appropriate therapy, while reducing overuse of unnecessary drugs, costs, and medication-related adverse events [1]. Diagnostic stewardship (DS) promotes the

**Abbreviations:** AAT, Appropriate antimicrobial therapy; AMR, Antimicrobial resistance; AMS, Antimicrobial stewardship; BAL, Bronchoalveolar lavage; BC, Blood culture; BCID, BC Identification; BSI, Blood stream infection; CDI, *Clostridioides difficile* infection; CRP, C-reactive protein; DS, Diagnostic stewardship; ESBL, Extended spectrum beta-lactamase; ID, Infectious diseases; IP-10, Interferon-inducible protein 10; LMIC, Low- and middle-income country; LOS, Length of hospital stay; MALDI-TOF MS, Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; MIC, Minimal inhibitory concentrations; mNGS, Metagenomic next generation sequencing; MRSE, Methicillin-resistant *Staphylococcus epidermidis*; MRSA, Methicillin-resistant *Staphylococcus aureus*; MSSA, Methicillin-susceptible *Staphylococcus aureus*; NAAT, Nucleic acid amplification testing; POC, Point-of-care; PCR, Polymerase chain reaction.

\* Corresponding author at: Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon.

E-mail address: [sk11@aub.edu.lb](mailto:sk11@aub.edu.lb) (S.S. Kanj).

appropriate use of the right diagnostic tools for every patient, to limit overuse and guide timely patient management. This strategy also enables early discontinuation of antimicrobial therapy, thereby limiting the risk of AMR and improving clinical outcomes [2]. DS is highly relevant in settings that involve immunocompromised and critically ill patients, where there is often a tendency for excessive use of microbiologic testing. It is also important in non-severe infections that do not always require testing, and where cultures of colonizers or contaminated samples might lead to unnecessary prescription of antimicrobial agents, such as sputum cultures in evident viral respiratory infections or blood cultures (BCs) in simple cellulitis [3,4]. Effective DS requires multidisciplinary collaboration between clinicians (including infectious diseases [ID] specialists and intensivists in critically ill patients) and clinical microbiologists, to ensure that diagnostic testing is timely and appropriate to optimize patient care and outcomes. Although the role of most members of the stewardship team is fairly consistent across different healthcare systems, the role of the medical microbiologist is variable. Microbiological expertise is crucial for AMS. The microbiology laboratory serves as a service department in many settings, particularly in most low- and middle-income countries (LMICs), whereas the medical microbiologist can be heavily involved in direct patient care and stewardship efforts in other healthcare models, particularly in Europe. Many factors contribute to the lower rates of AMR and antibiotic use that are observed in high-income countries. For instance, the availability of laboratory infrastructure and trained personnel, rigorous infection prevention and control, availability of novel diagnostics and the involvement of medical microbiologists in direct patient care all contribute to improved stewardship. Furthermore, diagnostic tests are more readily available in high-income countries, whereas LMICs are more likely to resort to appropriate diagnostics after treatment failure, thus creating reporting bias of AMR [5].

Many diagnostic tools have been developed in recent years to support the implementation of DS, including point-of-care (POC) tests and advanced molecular tools; however, the concept of DS is yet to be widely recognized and incorporated into regular clinical practice. This may be due to the lack of awareness regarding its potential to reduce inappropriate antimicrobial prescription and healthcare-related costs. DS prioritizes simple and basic diagnostics, and regulates the use of novel diagnostics that may not be available in low-resource settings or might impose excessive costs compared with conventional tests [6].

This review provides an insight into areas of the diagnostic pathway where DS may be of great importance, and highlights the role of novel tools in DS. Also covered is the importance of DS in five commonly encountered infectious syndromes, as well as the challenges of the implementation of effective and durable DS. Herein are described the microbiological aspects of DS further topics relevant to DS, such as chemistry (biomarkers) and imaging studies, are beyond the scope of this paper.

## 2. Diagnostic stewardship across the diagnostic pathway

The diagnostic pathway can be divided into three main phases: the pre-analytical, analytical, and post-analytical phases. DS is important across all three phases to ensure judicious use of diagnostic tools.

In the first step of the pre-analytical phase, the appropriate test is chosen after careful consideration of the clinical signs and symptoms. In addition to rational considerations whether or not to test, healthcare professionals should use clinical practice guidelines to optimize the use of diagnostic tools [7]. Accuracy, availability, cost-effectiveness, turnaround time and clinical impact are ideal characteristics that affect the choice of testing [8]. However, the diagnostic performance of a test also depends on the type of specimen

used and the time of collection. It is important to avoid tests that are either low-yield or carry a high risk of false positivity [9,10]. Similarly, diagnostics that are unlikely to affect patient management should be avoided [11]. Hence, the chosen diagnostics should be tailored to the pre-test probability of the disease, so that treatment choice can be supported by accurate and clinically relevant results [12]. This is important when dealing with acute pharyngitis, for example, where requesting streptococcal antigen or throat culture should be guided by the pre-test probability of the likelihood of bacterial pharyngitis.

Once appropriate testing is decided, proper sampling is crucial to maximize yield [2]. Guidance is widely available for common specimens (urine, blood, stool, respiratory samples, wound and genital swabs) as summarized in Table 1. During the analytical phase, the microbiology lab plays an important role in reducing unnecessary testing. Sample rejection is an intervention that has consistently shown great potential to reduce unnecessary testing and treatment. For instance, laboratories may not perform urine culture in the absence of significant pyuria, except in neutropenic patients, or refuse *Clostridioides difficile* infection (CDI) testing for non-loose stools. Specific institutional criteria should be established by ID specialists and microbiologists to avoid testing inappropriate samples. Also, microbiologists should quickly report inappropriately sampled, damaged or unsealed samples.


During the post-analytical phase, multidisciplinary interventions are necessary to enable correct interpretation of results. The integration of these interventions in the electronic medical record (EMR), whenever available, can improve communication and enable timely decision-making [7]. It is important that results are reported quickly to reduce time to optimal antimicrobial therapy. Furthermore, selective susceptibility reporting, where broad-spectrum antimicrobial susceptibility is not reported if the isolate is susceptible to narrow-spectrum agents, has been attempted and has shown promising results [13]. Modified reporting of culture results can also reduce unnecessary treatment by indicating probable colonization rather than infection [14]. Medical microbiologists are responsible for reporting results in a way that guides clinicians, and they play a key role in the multidisciplinary team to improve interpretation of results and encourage clinicians to discontinue treatment when deemed unnecessary (Scheme 1) [15].

## 3. Integrating novel diagnostic tools in the diagnostic pathway

Delay of appropriate antimicrobial therapy (AAT) has been associated with increased mortality in many instances [16]. Clinicians are often torn between giving broad-spectrum empirical therapy to cover a broad range of pathogens, including resistant organisms, and narrowing the spectrum to avoid the future emergence of resistance. For example, outcomes of patients with blood stream infection (BSI) due to *Pseudomonas aeruginosa* or methicillin-resistant *Staphylococcus aureus* (MRSA) may be heavily compromised if empirical therapy does not cover such resistant organisms. Hence, rapid pathogen identification and susceptibility testing may improve time to AAT and reduce mortality [17,18]. In addition, timely identification may also reduce the length of hospital stay (LOS) and healthcare costs [19,20]. In general, rapid initiation of AAT is mainly hindered by the long turnaround time of standard culturing techniques, identification, and susceptibility testing. POC tests and new techniques, such as molecular tests, reduce time to identification and may even detect markers of resistance to commonly used antimicrobials (Table 2). Implementing POC tests in routine practice requires careful consideration of the impact on patient care. Ideally, diagnostic tests should be accurate, rapid, sensitive, and specific. Portable tests that do not require technical skills for operation and that use heat-stable reagents provide on-demand POC testing, are cost-effective for patient care, accommodate a broad

**Table 1**  
Best practices for sample collection, preparation and transportation during the pre-analytical phase [2].

General considerations	<ul style="list-style-type: none"> <li>- Sampling by well trained professionals</li> <li>- Sampling prior to antimicrobial initiation</li> <li>- Proper labeling with a unique patient identifier, name, date of birth, specimen type, date of collection, hospital, or community origin</li> <li>- Transportation with clinical information</li> <li>- Encourage judicious use of novel diagnostics</li> </ul>
Urine cultures	<ul style="list-style-type: none"> <li>- Patient education on reducing contamination (clean catch)</li> <li>- Prompt transportation or refrigeration to reduce proliferation of contaminants</li> </ul>
Blood cultures	<ul style="list-style-type: none"> <li>- Encourage peripheral venipuncture sampling over central line sampling</li> <li>- Attempt to obtain two samples with adequate blood volume</li> </ul>
Respiratory cultures	<ul style="list-style-type: none"> <li>- Swab both nostrils and pharynx to increase the yield of nasopharyngeal sampling</li> <li>- Provide patients with proper instructions on providing expectoration for sputum culture</li> <li>- Consider distal sampling (like bronchoalveolar lavage [BAL], mini-BAL, bronchial washing), if possible, to increase diagnostic yield</li> </ul>
Throat cultures	<ul style="list-style-type: none"> <li>- Avoid throat cultures when clinical history is inconsistent with bacterial infection (acute viral infection)</li> </ul>
Stool culture and <i>Clostridioides difficile</i> toxin and polymerase chain reaction	<ul style="list-style-type: none"> <li>- Collect in a clean container</li> <li>- Keep at room temperature and transport within 2 hours of sampling</li> </ul>
Genital swabs for sexually transmitted diseases culture and polymerase chain reaction	<ul style="list-style-type: none"> <li>- For cultures, inoculate into growth medium on the bedside to improve the detection of <i>Neisseria gonorrhoea</i></li> <li>- Transport quickly</li> </ul>
Wound swab	<ul style="list-style-type: none"> <li>- Ensure deep wound culturing whenever possible</li> <li>- Favor needle aspiration from wound borders or tissue cultures from surgical debridement to avoid contamination and improve diagnostic yield</li> </ul>



**Scheme 1.** Diagnostic stewardship involving multidisciplinary teams across the diagnostic pathway.

range of clinical samples, and are highly desirable [7]. In addition, novel diagnostic tools can identify a small microbial load on uncultured samples.

POC testing is affordable, sensitive, specific, user-friendly, and rapidly accessible in most settings. It has a great advantage, particularly in LMICs, where resources to advance DS and AMS are lacking. POC testing has often been shown to optimize management, including avoiding neonatal complications through POC testing for group B streptococcal carriage [21]. By rapidly identifying the responsible pathogen, POC testing enables more targeted antimicrobial treatment.

i. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS)

MALDI-TOF MS is a novel, rapid and reliable diagnostic tool that enables rapid turnaround time and minimal cost of consumables. The technique relies on the determination of the time-of-flight of ionized particles of microbial organisms to identify the isolated pathogen (including mycobacteria and fungi) and even detects resistance markers [22–24]. The turnaround time of less than 1 h is far shorter than conventional methods and has reduced time to identification by up to 48 h [25]. However, it is limited by the need

**Table 2**  
Novel diagnostic tools for the identification of organisms causing bloodstream infection.

Assay	Detected pathogens	Resistance markers	Turnaround time*
PNA-FISH	<b>Gram positive</b> <i>Staphylococcus aureus</i> and coagulase-negative staphylococci <i>Enterococcus faecalis</i> and other enterococci	No	1.5–3 h
QuickFISH	<b>Gram negative</b> <i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i>	No	<30 min
Gene Xpert MRSA	<b>Gram positive</b> <i>Staphylococcus aureus</i>	<i>mecA</i>	< 1 h
Verigene Gram-positive	<i>Staphylococcus aureus</i> and coagulase-negative staphylococci <i>Streptococcus</i> spp. <i>E. faecalis</i> and <i>E. faecium</i> <i>Listeria</i> spp.	<i>mecA</i> , <i>vanA</i> , <i>vanB</i>	2.5 h
Verigene Gram-negative	<i>E. coli</i> <i>Shigella</i> spp. <i>K. pneumoniae</i> and <i>K. oxytoca</i> <i>P. aeruginosa</i> <i>Serratia marcescens</i> <i>Acinetobacter</i> spp. <i>Proteus</i> spp. <i>Citrobacter</i> spp. <i>Enterobacter</i> spp.	KPC, NDM, CTX-M, VIM, IMP, OXA	2 h
MALDI-TOF	Gram-positive and Gram-negative bacteria, mycobacteria	Multiple	10–30 min
FilmArray (BCID)	<b>Gram positive</b> <i>S. aureus</i> and other staphylococci <i>Streptococcus</i> spp. <i>Enterococcus</i> spp. <i>Listeria monocytogenes</i>	<i>mecA</i> , <i>vanA</i> , <i>vanB</i>	1 h
	<b>Gram negative</b> <i>Hemophilus influenzae</i> <i>Neisseria meningitidis</i> <i>Enterobacter cloacae</i> complex <i>E. coli</i> <i>K. pneumoniae</i> and <i>K. oxytoca</i> <i>P. aeruginosa</i> <i>Serratia marcescens</i> <i>Acinetobacter baumannii</i> <i>Proteus</i> spp.	IMP, KPC, NDM, VIM, OXA-48-like, <i>mcr-1</i> , CTX-M,	

\* Once BCs are positive

to perform conventional cultures first. In addition, its performance is suboptimal in polymicrobial samples and is rarely accessible in LMICs. For instance, an evidence-based intervention that integrated MALDI-TOF, rapid antimicrobial susceptibility testing, and near-real-time AMS reported a significant difference in median time to identification (36.6 h vs 11 h,  $P < 0.001$ ), median time to obtain susceptibility (47.1 h vs 24.4 h,  $P < 0.001$ ) and median time to adjust therapy (75 h vs 29 h,  $P = 0.004$ ). These findings prove that combining MALDI-TOF and AMS decreases LOS and costs and, most importantly, time to initiation of optimal therapy [26]. In addition, a randomized controlled trial (RCT) including 1005 patients that compared MALDI-TOF to conventional microbiological methods (Gram stain, standard cultures) showed that there were no significant differences between the two groups regarding the proportion of patients receiving optimal antimicrobial therapy in the absence of an AMS program [27]. Despite the benefits of MALDI-TOF, it does not spare the time for culturing, which can take more than 24 hours.

#### ii. Polymerase chain reaction (PCR)

On the other hand, molecular diagnostics detect small microbial loads with high sensitivity and specificity. For example, a PCR-

based detection system designed to identify MRSA or methicillin-susceptible *S. aureus* (MSSA) on positive BC or wound specimens has been shown to have 98.3–100% sensitivity and 98.6–99.4% specificity [28]. The Gene Xpert MRSA can detect MRSA by reverse transcriptase (RT)-PCR in around 1 h, including the *mecA* gene mutation with a sensitivity of 98.1% and a specificity of 99.6% [29].

Detection of multiple pathogens and some resistance genes is also possible with highly sensitive and specific microarray-based techniques with a turnaround time of 1–2.5 h [30–32]. In fact, the use of PCR assays to rapidly identify MRSA/MSSA has been associated with a reduced time to AAT, LOS, and healthcare costs when paired with AMS [33,34]. Using rapid multiplex PCR for BSI has been shown to decrease the use of broad-spectrum antibiotics in an RCT. The addition of AMS increased the opportunity for de-escalation of therapy [15].

Multiplex PCR methods like the Verigene, can detect many Gram-positive and Gram-negative organisms, and many genes associated with AMR (Carbapenemases, *mecA*, *VanA*, *VanB*) in 2–2.5 h. The Verigene has been reported to have 96.4% concordance to the species level for BC during a 5-year retrospective analysis. In addition, it had a positive percent agreement (PPA) for MRSA and methicillin-resistant *Staphylococcus epidermidis* (MRSE)



of 100% compared with conventional antimicrobial susceptibility testing. However, a high false positive rate of 43% was observed for *Streptococcus pneumoniae* and has been reported in other studies. Hence, adjunct testing methods, such as bile solubility testing or antigen testing, may be necessary for *S. pneumoniae* [32,35]. The Verigene has also shown a high concordance for the identification of Gram-negative organisms (99% for monomicrobial BC and 83.3% for polymicrobial BC) and for resistance markers (92.3%), with a median time to bacterial identification of 21 h and to susceptibility results of 43 h. The Verigene assay could enable earlier evidence-based management for bacteremic patients, but it cannot replace phenotypic methods as solid medium isolation is essential for polymicrobial cultures to identify undetected organisms and to obtain minimal inhibitory concentrations (MIC) [36].

Another molecular tool, the Biofire FilmArray BC identification assay, is a multiplex PCR assay that identifies many Gram-positive and Gram-negative organisms with a turnaround time of 1 h, and detects the *mecA*, Van A, and Van B resistance genes of Gram-positive bacteria as well as carbapenemase, extended spectrum beta-lactamase (ESBL), and colistin resistance genes for Gram-negative organisms [22]. The use of the FilmArray BC Identification (BCID) panel was compared to standard culture and antimicrobial susceptibility testing in a single-center RCT. A third arm was included in the study where BCID was used alongside real-time AMS. In the BCID arm, pathogen identification was 21 h faster and broad-spectrum antibiotic use was reduced. However, significantly quicker de-escalation was only reported in the group using BCID plus AMS [37].

Respiratory infections are an important cause of overuse and inappropriate use of antimicrobials. Many multiplex PCR panels, including the BioFire FilmArray RP, Nanosphere Verigene RV+ test, and Hologic Gen-Probe Prodesse, are available for these infections. These assays can provide valuable information for decision-making regarding initiation and choice of antimicrobial therapy in patients with positive results. However, the possibility of contamination must always be considered, particularly if the pre-test probability is low [38].

### iii. Metagenomic next generation sequencing (mNGS)

Compared to conventional methods, mNGS can accurately identify multiple pathogens and their resistance genes in a short period of time without the need for culture [39]. A meta-analysis evaluating the clinical use of mNGS revealed that it had an excellent performance and high diagnostic efficacy for ID. However, it may not perform as well with RNA viruses, fungi, and intracellular bacteria [40]. Conventional culture diagnostic yield is severely affected after administration of antimicrobials, whereas mNGS can still detect the causative organism, even after initiation of antimicrobials, which can help improve the appropriateness of antimicrobial agents [41]. In addition, mNGS can be affected by contaminating DNA and cannot differentiate colonization from infection [42]. Hence, DS is crucial when using mNGS in the clinical setting to avoid the risk of false positives and unnecessary antimicrobial therapy. Further clinical studies are needed to assess its utility for DS.

### iv. Host response-based diagnostics

Host response-based diagnostics offer a new perspective to ID diagnoses, particularly gene expression signatures. Interestingly, methods that rely on identifying the human body's reaction to a particular disease may be able to differentiate between noninfectious and infectious etiologies of illness, notably viral or bacterial [43]. For instance, an assay including a 3-peptide panel of interferon-inducible protein 10 (IP-10), TNF-related apoptosis-inducing ligand (TRAIL), and C-reactive protein (CRP) has been used to differentiate viral from bacterial acute respiratory illness,

alone or combined with other biomarkers [44–46]. In a retrospective analysis comparing gene expression to clinical judgment, gene expression correctly differentiated bacterial, viral, or noninfectious illness in 74.1% of subjects and avoided overdiagnosis and inappropriate treatment, which was seen in 33.3% of cases in the control arm. Gene expression was also found to have a significantly higher weighted accuracy (79.9%) compared with procalcitonin (71.5%) and clinical judgment (76.3%) [47]. However, more trials are needed to decide whether these findings translate into improved patient outcomes.

In light of the accumulating evidence regarding the accuracy of novel diagnostic techniques, the need to develop and optimize new microbiological diagnostics is greater than ever, particularly for DS. The availability of novel diagnostics should not replace basic diagnostics, which are less costly and have been repeatedly proven to reduce inappropriate antimicrobial use [48,49]. To expedite approvals of diagnostic tests, the Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND study) has been conceived. In this study, the same sample is used to evaluate the effectiveness of many experimental diagnostics to maximize the generation of valuable data on their efficacy, with the goal of improving the accessibility to novel diagnostics. Initially, the MASTERMIND study evaluated nucleic acid amplification testing (NAAT) for oropharyngeal and rectal gonorrhea and chlamydia. Results showed that the use of NAAT in the emergency department setting led to a significant reduction of excessive and inappropriate antimicrobial treatment for women compared with standard of care [50]. The Platforms for Rapid Identification of MDR-Gram Negative Bacteria and Evaluation of Resistance (PRIMER) studies have been conducted with the primary goal of improving the interpretation of the results of rapid molecular diagnostic (RMD) platforms. The findings showed that RMD platforms can provide valuable information to guide empirical antimicrobial therapy [51–53].

There is a consistently increasing variety of available diagnostic tests, and their abundance may lead to overuse and increased healthcare costs [54,55]. Research and development in the diagnostics field is continuously generating new tools. Ultrasensitive quantitative toxin assays [56], NAAT PCR cycle threshold analysis [57], PCR-electrospray identification [58], targeted metagenomics [59], and many other tools are being developed with the primary focus of advancing DS. Many studies have shown that rapid diagnostics are optimized by the presence of a multidisciplinary AMS that oversees the interpretation of the results [26,60–62].

## 4. Rationale behind diagnostic stewardship in common infectious syndromes

There are many reasons why healthcare providers disregard DS principles in daily practice, including absence of good clinical microbiological diagnostics, lack of knowledge of guidelines, misleading reporting of results, disease severity, or lack of personnel training. In the setting of critical illness, physicians are at risk of overprescribing antimicrobials to reduce mortality. For instance, up to 50% of patients treated with antibiotics for suspected ventilator-acquired pneumonia (VAP) in the ICU may not actually have VAP [63]. This is likely driven by the significant increased mortality when appropriate antimicrobial therapy is delayed in such patients [64]. Additionally, the availability of obtaining respiratory samples in these patients may increase the risk of treating colonizers in the absence of infection [64,65]. Clinicians should consider pre-test probability, microbiology, clinical score, and biomarkers (e.g., CRP, procalcitonin) when making treatment decisions.

Regarding bloodstream infections (BSI), the absence of clear-cut indications for ordering BCs may lead to unnecessary treatment, increased LOS, and costs [11,66]. In fact, only 5–15% of BCs yield positive results, with up to 56% being contaminations [67]. De-

spite being weakly correlated with BSI, fever or leukocytosis are the most common drivers for ordering BCs [68,69]. Pre-test probability and the effect on management should be considered prior to ordering BCs. In low-risk patients, BCs are unlikely to affect the management of the patient and should not be ordered if there is no concern for sepsis or septic shock [11]. BCs prior to initiation of antimicrobials may be warranted if primary infection site sampling is not possible, regardless of the probability of sepsis. Most importantly, critically ill infected patients should have BCs drawn promptly to initiate empirical antimicrobial therapy [11]. Individual centers should also be periodically monitoring their positivity rates and contamination rates to inform the end users and plan the needed educational activities to achieve the DS goals.

Asymptomatic bacteriuria is one of the most common causes of unnecessary antimicrobial use [70]. The decision to obtain urine cultures should be based on high clinical suspicion of urinary tract infection (UTI) to avoid unnecessary testing, excessive use of antimicrobials, emergence of resistance, and complications, such as CDI and drug-related toxicity [71–73]. However, in a subset of patients, such as pediatric, pregnant, neutropenic, or renal transplant patients, or those requiring urological procedures, clinicians should have a lower threshold for ordering urine cultures [73]. The absence of pyuria and bacteriuria on microscopy has a negative predictive value of 97–100% for UTI [9,74]. On the other hand, the signs and symptoms of UTI in critically ill patients may be atypical and misleading, particularly in the presence of an indwelling urinary catheter. Catheter-associated bacteriuria (CAB) is very common, with an acquisition rate of 3–5% per catheter-day [73]. In that case, it is often indicative of colonization rather than true infection and might be delayed but not prevented by antimicrobials. In critically ill patients with a high index of suspicion of an infectious process, in the absence of pyuria, urine cultures should only be performed after other infectious syndromes are ruled out.

Rapid and accurate diagnostic tools are crucial to reduce morbidity and mortality associated with central nervous system (CNS) infections like meningitis and encephalitis. With 90% accuracy and a turnaround time of 1 h, microarray PCR can rapidly identify causative agents in cerebrospinal fluid (CSF) [75]. Also, it can detect smaller quantities of pathogens and may be useful in patients who received antimicrobials prior to lumbar puncture [76]. In the pediatric population, microarray can increase pathogen identification, but requires further confirmation [77]. However, false positives and overdiagnosis are pertinent issues with such highly sensitive tests, particularly in patients with a low pre-test probability [75,78]. In the absence of evidence-based guidance, DS efforts are crucial to decrease excessive use of microarray testing and subsequent unnecessary antimicrobial prescription [65,79–82].

CDI is a common complication of antimicrobial treatment among hospitalized patients [83]. Unlike toxin or antigen-based tests (toxin A, toxin B, glutamate dehydrogenase [GDH]), new molecular diagnostics have a sensitivity that approaches 100% [84]. However, it is estimated that over half of patients with positive NAAT results are colonized, rather than infected, by *C. difficile* [85,86]. The contrast between high-income countries and LMICs is significant. On one hand, colonization rates are increasing with the adoption of NAAT instead of antigen- or toxin-based testing by most hospitals in high-income countries [87]. On the other hand, NAAT is not as widely available in LMICs, and the diagnosis of CDI is suboptimal [88]. Thus, there is a need for DS for CDI that takes into account the availability of diagnostic tests. The absence of approved biological markers with a high specificity for CDI further complicates the diagnosis when clinical signs and *C. difficile* testing are inconclusive [87]. Avoiding unnecessary treatment is essential in this population, given that antimicrobials may aggravate the underlying dysbiosis in patients with CDI [89,90]. With the wide

availability of highly sensitive diagnostics and the lack of prospectively validated criteria to diagnose CDI [91–93], inappropriate testing may be common in the absence of DS guidance [94–96]. Test results should be interpreted with consideration of clinical suspicion of CDI. If clinicians opt for toxin-based testing, they should consider that the negative predictive value of toxin assays may not be enough to rule out CDI [97,98]. Although patients with negative toxin findings may have a lower risk of severe disease and complications, the absence of toxins does not rule out CDI [85,99].

According to the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), NAAT can be used alone or in combination with GDH or toxin testing as part of a diagnostic algorithm [95]. Although NAAT has a high sensitivity, it may lead to a high rate of false positives and increased costs [85]. In LMICs, the high cost and unavailability of NAAT have led many centers to only use toxin immunoassays, despite their low sensitivity. Using toxin assays alone can lead to a high rate of false negatives and has serious implications for patient outcomes and infection prevention and control [100]. A cost analysis study comparing multiple algorithms for the diagnosis of CDI showed that rapid toxin immunoassay and GDH followed by arbitrary NAAT is the best approach for the diagnosis of CDI and had the lowest cost, whereas NAAT alone had the highest cost of illness management [88].

Ultimately, a multidisciplinary team approach involving infection control and prevention, and auditing and quality control, are essential practices that can reduce CDI rates, unnecessary CDI antimicrobial treatment duration, and mortality [101,102].

**Table 3** highlights studies that have reported the impact of DS interventions on patient outcomes, hospitalization costs, appropriateness of therapy, and healthcare provider knowledge. The IDSA has published guidelines addressing the diagnosis of VAP [103], CDI [95], and asymptomatic bacteriuria [73]. These guidelines reiterate the need for clinicians to consider both clinical and microbiological criteria, routinely reevaluate for the possibility of a non-infectious process, judiciously use novel diagnostics, and discontinue antimicrobial therapy when deemed unnecessary.

## 5. Challenges of implementing diagnostic stewardship

There are important barriers to implementing successful DS principles in different settings. In the ICU, clinicians are often faced with particularly challenging scenarios, where severe presentations and overlapping organ dysfunctions lead to hesitancy in delaying the initiation or de-escalation of antimicrobial therapy, even when an infectious etiology is not proven. Although reducing unnecessary testing decreases the occurrence of unnecessary treatment, it might increase the risk of delaying diagnosis and appropriate treatment of infections. This may correlate with worse outcome, particularly in high-risk patients, such as neutropenic or bone marrow transplant recipients. DS guidelines must identify the optimal strategy for testing that minimizes overdiagnosis and unnecessary treatment without putting critical patients at risk.

Furthermore, in LMICs, DS implementation is hindered by inadequate medical microbiological knowledge and governance, limited diagnostic tools and funding support [118]. The scarcity of DS and AMS specialists and required (old and new) antimicrobials in these countries, in addition to the lack of physicians' education and training, often means physicians are reluctant to modify current practices of antimicrobial prescribing, particularly when pressured by patients demanding antibiotic prescriptions [119]. For this reason, effective collaboration among ID experts, critical care physicians, and medical microbiologists is required to optimize patient care and offer evidence-based DS recommendations to hospitals in such settings. Research on the implementation of AMS programs in LMICs is crucial, as interventions that are effective in low-resource

**Table 3**  
Interventions that have shown effectiveness at promoting DS.

Author	Intervention	Outcome	Recommendation
VAP Hellyer et al. [104]	Using levels of IL-1 $\beta$ and IL-8 to discontinue therapy	No effect on AMS due to the reluctance of physicians to discontinue therapy	Conventional and novel biomarkers can be helpful when deciding on the duration of treatment Risks vs. benefits should be weighed in deciding which sampling technique to use as non-invasive sampling may be sufficient in most cases Modified reporting is essential for AMS efforts and unnecessary treatment reduction Gram-stain on respiratory cultures may substantially reduce unnecessary therapy, and is a widely available and inexpensive means to promote DS, particularly in LMICs
Berton et al. [105]	Invasive sampling (BAL, mini-BAL, bronchial washing) vs. non-invasive sampling (ETA)	No difference in mortality, ICU LOS, days on MV, or changes of antimicrobials	
Musgrove et al. [106]	Reporting sputum cultures as “no MRSA and no <i>Pseudomonas</i> spp.” vs. “polymicrobial respiratory flora”	De-escalation increased from 39% to 73% ( $P<0.001$ ) Median duration of anti-pseudomonal antimicrobials decreased from 7 to 5 days ( $P<0.001$ ) Significant decrease of MDR isolation from respiratory cultures from 8% to 1%	
Yoshimura et al. [107]	Gram-stain guided vs. standard empirical therapy (covering MRSA and <i>Pseudomonas</i> spp.)	Decreased use of anti-pseudomonal and anti-MRSA drugs No significant difference in coverage rates (92% in interventional arm vs. 95% in control)	
BSI Copeland-Harpelin et al. [108]	Using a clinical decision tool using 3 criteria Post-operative BCs for post-operative BSIs (hypotension, fever, >2 days post-operatively)	85% reduction of BC orders while maintaining the same diagnostic yield	In the absence of hypotension and fever before 2 post-operative days, BCs are likely unnecessary Institutional guidance and training should be provided to HCWs to reduce excessive testing that may lead to unnecessary treatment Follow-up BCs may not be useful in patients who are responding well to treatment, except in cases of <i>S. aureus</i> , endovascular infection, <i>S. lugdunensis</i> , and persistence of signs of infection after 72 h of therapy
Fabre et al. [109]	Quality intervention study providing education and algorithms that help guide ordering new or repeat BCs	Significant reduction in BC orders BC positivity rate increased from 8.1% to 11.5% ( $P<0.001$ ) in the ICU No effect on mortality and readmission rates	
Scheer et al. [110]	BCs after initiation of antimicrobials	BC positivity rate was reduced by 20% when obtained during antimicrobial therapy	
UTI Lee et al. [111]	Two-step algorithm sending urine samples to culture only if urinalysis shows pyuria	Significant reduction of antimicrobial use without affecting mortality Improved clinicians' confidence when withholding antimicrobials	Urine samples from asymptomatic patients with no pyuria on urinalysis should not be cultured to reduce the risk of treating asymptomatic bacteriuria Modified reporting of urine samples suggestive of ASB improves the appropriateness of antimicrobial therapy Two-step algorithm may also be used for CAUTI in critically ill patients where MDR burden is higher
Daley et al. [13]	Reporting urine samples as “possibility of being asymptomatic bacteriuria” vs. standard reporting Clinicians needed to call the microbiology lab to obtain identification and AST results	Higher rates of appropriate antimicrobial therapy were achieved in the intervention arm (80% vs. 52.7%, $P=0.002$ )	

(continued on next page)



Table 3 (continued)

Author	Intervention	Outcome	Recommendation
Epstein et al. [112]	Reflex urine protocol in patients suspected to have CAUTI	Reduced the rates of culturing and CAUTIs without affecting patient outcomes in critically ill patients	
CNS infections Broadhurst et al. [113]	Restricting CSF microarray testing to samples showing pleocytosis in immunocompetent adults	Significant increase of microarray testing yield from 11.5% to 18.6% 75% of false-positive results were avoided without any additional false-negative results Excluding immunocompromised patients, normal CSF WBC count was found to have a very high overall negative predictive value of 98-100% for nonviral agents	Restricting microarray testing to immunocompetent adult patients with CSF anomalies reduces unnecessary testing and improves diagnostic yield
CDI White et al. [10]	Reminder to check for laxative use when ordering stool testing	Reduction of inappropriate testing	Avoid testing for CDI in patients who are on laxatives or patients with low clinical suspicion of CDI Use the EMR to implement soft (review prior to ordering) or hard (block ordering) stops that promote DS The microbiology lab should not test non-loose stools or samples obtained from patients with low-pretest probability of CDI
Quan et al. [114]	Real-time checking of clinical criteria suggestive of CDI when ordering stool testing	Improved testing appropriateness Reduced hospital-onset CDI	
Quan et al. [114]	Blocking stool test order when clinical criteria are absent	56% reduction was observed for CDI testing and 54% reduction for HO-CDI laboratory-identified events	
Christensen et al. [115]	Implementation of a clinical review and pre-authorization protocol for CDI testing	Reductions in HO-CDI and oral vancomycin prescription	
Brecher et al. [116]	Allowing labs to refuse non-loose stools for stool testing	43% decrease in CDI testing was noted along with a 60% decrease in CDI events	
Truong et al. [117]	Microbiology labs were allowed to cancel CDI testing orders in the absence of clinical criteria (such as $\geq 3$ loose stools in the past 24 h in the absence of laxative use in the past 48 h)	32% decrease in CDI testing and did not have any significant increases in ICU admission or 30-day all-cause mortality	

VAP, ventilator-acquired pneumonia; BAL, bronchoalveolar lavage; ICU, intensive care unit; LOS, length of stay; ETA, endotracheal aspirate; MV, mechanical ventilation; MDR, multidrug resistant; MRSA, methicillin-resistant *S. aureus*; EAT, empiric antimicrobial therapy; BSI, bloodstream infection; BC, blood culture; HCW, healthcare workers; UTI, urinary tract infection; CAUTI, catheter-associated urinary tract infection; LMICs, low- and middle-income countries; ASB, asymptomatic bacteriuria; CNS, central nervous system; CSF, cerebrospinal fluid; WBC, white blood cells; CDI, *Clostridioides difficile* infection; HO-CDI, hospital-occurring CDI; EMR, electronic medical record.

settings may differ from those that have been successful in larger hospitals in high-income countries.

Although novel diagnostic tools have been shown to contribute to the appropriate use of antimicrobials in various clinical syndromes, the use of these tools is still significantly limited by their high cost and unavailability, particularly in LMICs. These techniques add to the healthcare financial burden, are time-consuming, and many require equipment and tools that are only available in well-resourced facilities [120]. However, some of these techniques may reduce antimicrobial use, LOS, and healthcare costs, and can be cost-effective when used judiciously. AMS teams should provide guidance on the proper use of these techniques within an institution. Global collaboration between all stakeholders, including industry corporations and governments, is essential to increase access to novel diagnostic tools across the world.

## 6. Conclusion

DS in ID management requires ordering the right test, for the right patient, at the right time to positively impact patients' outcomes without overusing (or underusing) the available tests. DS is

an important concept that has been applied in settings where the clinical microbiology laboratory played a role beyond a service laboratory, but it is still lacking in many countries, and requires further development and elaboration. Healthcare facilities need to engage in DS by investing in hiring qualified clinical microbiologists, who can help establish clear criteria for ordering various tests and acquiring the appropriate technology for patients. Highly sensitive novel diagnostics should not replace clinical input and basic tests. Large-scale research is needed to provide further evidence of the benefits of DS on patient outcomes and healthcare costs. Moreover, studies from low-resource settings are needed to better understand how to implement DS in such contexts. As healthcare facilities become motivated to implement DS, providers and clinicians must be trained in effective principles of DS. Diagnostic tools and laboratory resources must be refined and made widely accessible across all settings to effectively inform clinical decisions and improve patient care. The impact of proper diagnostics and expertise is considerable and much needed. Good clinical microbiology should embrace DS as a core activity to enable successful AMS and infection prevention. Finally, the potential of DS cannot be fully reached unless paired with proper AMS.

## Declarations

**Acknowledgements:** We would like to thank Dr Ray Saginur for reviewing the manuscript and providing his input.

**Funding:** No funding.

**Competing interests:** There are no conflicts of interest.

**Ethical approval:** Not required.

**Sequence information:** Not applicable.

## References

- Core Elements of Hospital Antibiotic Stewardship Programs | Antibiotic Use | CDC 2022. <https://www.cdc.gov/antibiotic-use/core-elements/hospital.html> (accessed December 14, 2022).
- World Health Organization Diagnostic stewardship: a guide to implementation in antimicrobial resistance surveillance sites. World Health Organization; 2016.
- Schouten J, De Waele J, Lanckohr C, Kourenti D, Haddad N, Rizk N, et al. Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns. *Int J Antimicrob Agents* 2021;58:106409. doi:10.1016/j.ijantimicag.2021.106409.
- Pickens CI, Wunderink RG. Principles and practice of antibiotic stewardship in the ICU. *Chest* 2019;156:163–71. doi:10.1016/j.chest.2019.01.013.
- Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. *Antimicrob Resist Infect Control* 2021;10:63. doi:10.1186/s13756-021-00931-w.
- Rolfé R, Kwobah C, Muro F, Ruwanpathirana A, Lyamuya F, Bodinayake C, et al. Barriers to implementing antimicrobial stewardship programs in three low- and middle-income country tertiary care settings: findings from a multi-site qualitative study. *Antimicrob Resist Infect Control* 2021;10:60. doi:10.1186/s13756-021-00929-4.
- Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, et al. Better tests, better care: improved diagnostics for infectious diseases. *Clin Infect Dis* 2013;57(Suppl 3):S139–70. doi:10.1093/cid/cit578.
- Patel R, Fang FC. Diagnostic stewardship: Opportunity for a laboratory-infectious diseases partnership. *Clin Infect Dis* 2018;67:799–801. doi:10.1093/cid/ciy077.
- Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. *Clin Infect Dis* 2004;38:1150–8. doi:10.1086/383029.
- White DR, Hamilton KW, Pegues DA, Hanish A, Umscheid CA. The impact of a computerized clinical decision support tool on inappropriate *Clostridium difficile* testing. *Infect Control Hosp Epidemiol* 2017;38:1204–8. doi:10.1017/ice.2017.161.
- Fabre V, Sharara SL, Salinas AB, Carroll KC, Desai S, Cosgrove SE. Does this patient need blood cultures? A scoping review of indications for blood cultures in adult nonneutropenic inpatients. *Clin Infect Dis* 2020;71:1339–47. doi:10.1093/cid/ciaa039.
- Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial stewardship: How the microbiology laboratory can right the ship. *Clin Microbiol Rev* 2017;30:381–407. doi:10.1128/CMR.00066-16.
- Daley P, Garcia D, Inayatullah R, Penney C, Boyd S. Modified reporting of positive urine cultures to reduce inappropriate treatment of asymptomatic bacteriuria among nonpregnant, noncatheterized inpatients: A randomized controlled trial. *Infect Control Hosp Epidemiol* 2018;39:814–19. doi:10.1017/ice.2018.100.
- Kenaa B, Richert ME, Claeys KC, Shipper A, Sullivan KV, Schrank GM, et al. Ventilator-associated pneumonia: Diagnostic test stewardship and relevance of culturing practices. *Curr Infect Dis Rep* 2019;21:50. doi:10.1007/s11908-019-0708-3.
- Banerjee R, Özenci V, Patel R. Individualized approaches are needed for optimized blood cultures. *Clin Infect Dis* 2016;63:1332–9. doi:10.1093/cid/ciw573.
- Vlieghe ER, Phe T, De Smet B, Veng HC, Kham C, Lim K, et al. Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. *PLoS One* 2013;8:e59775. doi:10.1371/journal.pone.0059775.
- Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006;34:1589–96. doi:10.1097/01.CCM.0000217961.75225.E9.
- Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest* 2009;136:1237–48. doi:10.1378/chest.09-0087.
- Beekmann SE, Diekema DJ, Chapin KC, Doern GV. Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges. *J Clin Microbiol* 2003;41:3119–25. doi:10.1128/JCM.41.7.3119-3125.2003.
- Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. *J Clin Microbiol* 1994;32:1757–62. doi:10.1128/jcm.32.7.1757-1762.1994.
- Kozel TR, Burnham-Marusch AR. Point-of-care testing for infectious diseases: Past, present, and future. *J Clin Microbiol* 2017;55:2313–20. doi:10.1128/JCM.00476-17.
- Kothari A, Morgan M, Haake DA. Emerging technologies for rapid identification of bloodstream pathogens. *Clin Infect Dis* 2014;59:272–8. doi:10.1093/cid/ciu292.
- Vrioni G, Tsiamis C, Oikonomidis G, Theodoridou K, Kapsimali V, Tsakris A. MALDI-TOF mass spectrometry technology for detecting biomarkers of antimicrobial resistance: current achievements and future perspectives. *Ann Transl Med* 2018;6:240. doi:10.21037/atm.2018.06.28.
- Dingle TC, Butler-Wu SM. MALDI-TOF mass spectrometry for microorganism identification. *Clin Lab Med* 2013;33:589–609. doi:10.1016/j.cll.2013.03.001.
- Paolucci M, Landini MP, Sambri V. Conventional and molecular techniques for the early diagnosis of bacteraemia. *Int J Antimicrob Agents* 2010;36(Suppl 2):S6–16. doi:10.1016/j.ijantimicag.2010.11.010.
- Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis JR, Land GA, et al. Integrating rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. *Arch Pathol Lab Med* 2013;137:1247–54. doi:10.5858/arpa.2012-0651-OA.
- Nadjim B, Dat VQ, Campbell JI, Dung VTV, Torre A, Tu NTC, et al. A randomised controlled trial of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) versus conventional microbiological methods for identifying pathogens: Impact on optimal antimicrobial therapy of invasive bacterial and fungal infections in Vietnam. *J Infect* 2019;78:454–60. doi:10.1016/j.jinf.2019.03.010.
- Wolk DM, Struelens MJ, Pancholi P, Davis T, Della-Latta P, Fuller D, et al. Rapid detection of *Staphylococcus aureus* and methicillin-resistant *S. aureus* (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. *J Clin Microbiol* 2009;47:823–6. doi:10.1128/JCM.01884-08.
- Buchan BW, Allen S, Burnham C-AD, McElvania TeKippe E, Davis T, Levi M, et al. Comparison of the next-generation Xpert MRSA/SA BC assay and the GeneOhm StaphSR assay to routine culture for identification of *Staphylococcus aureus* and methicillin-resistant *S. aureus* in positive-blood-culture broths. *J Clin Microbiol* 2015;53:804–9. doi:10.1128/JCM.03108-14.
- Blaschke AJ, Heyrend C, Byington CL, Fisher MA, Barker E, Garrone NF, et al. Rapid identification of pathogens from positive blood cultures by multiplex polymerase chain reaction using the FilmArray system. *Diagn Microbiol Infect Dis* 2012;74:349–55. doi:10.1016/j.diagmicrobio.2012.08.013.
- Altun O, Almuhayawi M, Ullberg M, Ozenci V. Clinical evaluation of the FilmArray blood culture identification panel in identification of bacteria and yeasts from positive blood culture bottles. *J Clin Microbiol* 2013;51:4130–6. doi:10.1128/JCM.01835-13.
- Buchan BW, Ginocchio CC, Manii R, Cavagnolo R, Pancholi P, Swyers L, et al. Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. *PLoS Med* 2013;10:e1001478. doi:10.1371/journal.pmed.1001478.
- Parta M, Goebel M, Thomas J, Matloobi M, Stager C, Musher DM. Impact of an assay that enables rapid determination of *Staphylococcus* species and their drug susceptibility on the treatment of patients with positive blood culture results. *Infect Control Hosp Epidemiol* 2010;31:1043–8. doi:10.1086/656248.
- Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with *Pseudomonas aeruginosa* infections. *Antimicrob Agents Chemother* 2013;57:2907–12. doi:10.1128/AAC.02365-12.
- Wojewoda CM, Sercia L, Navas M, Tuohy M, Wilson D, Hall GS, et al. Evaluation of the Verigene Gram-positive blood culture nucleic acid test for rapid detection of bacteria and resistance determinants. *J Clin Microbiol* 2013;51:2072–6. doi:10.1128/JCM.00831-13.
- Dodémont M, De Mendonça R, Nonhoff C, Roisin S, Denis O. Performance of the Verigene Gram-negative blood culture assay for rapid detection of bacteria and resistance determinants. *J Clin Microbiol* 2014;52:3085–7. doi:10.1128/JCM.01099-14.
- Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. *Clin Infect Dis* 2015;61:1071–80. doi:10.1093/cid/civ447.
- Huang H-S, Tsai C-L, Chang J, Hsu T-C, Lin S, Lee C-C. Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. *Clin Microbiol Infect* 2018;24:1055–63. doi:10.1016/j.cmi.2017.11.018.
- Goldberg B, Sichtig H, Geyer C, Ledebner N, Weinstock GM. Making the leap from research laboratory to clinic: Challenges and opportunities for next-generation sequencing in infectious disease diagnostics. *MBio* 2015;6:e01888-01815. doi:10.1128/mBio.01888-15.
- Liu J, Zhang Q, Dong Y-Q, Yin J, Qiu Y-Q. Diagnostic accuracy of metagenomic next-generation sequencing in diagnosing infectious diseases: a meta-analysis. *Sci Rep* 2022;12:21032. doi:10.1038/s41598-022-25314-y.
- Zhang Y, Cui P, Zhang H-C, Wu H-L, Ye M-Z, Zhu Y-M, et al. Clinical application and evaluation of metagenomic next-generation sequencing in suspected adult central nervous system infection. *J Transl Med* 2020;18:199. doi:10.1186/s12967-020-02360-6.
- Messacar K, Parker SK, Todd JK, Dominguez SR. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. *J Clin Microbiol* 2017;55:715–23. doi:10.1128/JCM.02264-16.
- Tsalik EL, Henao R, Nichols M, Burke T, Ko ER, McClain MT, et al. Host gene expression classifiers diagnose acute respiratory illness etiology. *Sci Transl Med* 2016;8:322ra11. doi:10.1126/scitranslmed.aad6873.

- [44] Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshten L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. *PLoS One* 2015;10:e0120012. doi:10.1371/journal.pone.0120012.
- [45] van Houten CB, de Groot JAH, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. *Lancet Infect Dis* 2017;17:431–40. doi:10.1016/S1473-3099(16)30519-9.
- [46] Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. *J Infect* 2016;73:177–80. doi:10.1016/j.jinf.2016.05.002.
- [47] Jaffe IS, Jaehne AK, Quackenbush E, Ko ER, Rivers EP, McClain MT, et al. Comparing the diagnostic accuracy of clinician judgment to a novel host response diagnostic for acute respiratory illness. *Open Forum Infect Dis* 2021;8:ofab564. doi:10.1093/ofid/ofab564.
- [48] Lubell Y, Chandna A, Smithuis F, White L, Wertheim HFL, Redard-Jacot M, et al. Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity. *Malar J* 2019;18:442. doi:10.1186/s12936-019-3059-5.
- [49] Do NTT, Ta NTD, Tran NTH, Than HM, Vu BTN, Hoang LB, et al. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial. *Lancet Glob Health* 2016;4:e633–41. doi:10.1016/S2214-109X(16)30142-5.
- [50] Gaydos CA, Ako M-C, Lewis M, Hsieh Y-H, Rothman RE, Dugas AF. Use of a rapid diagnostic for *Chlamydia trachomatis* and *Neisseria gonorrhoeae* for women in the emergency department can improve clinical management: Report of a randomized clinical trial. *Ann Emerg Med* 2019;74:36–44. doi:10.1016/j.annemergmed.2018.09.012.
- [51] Evans L, Rhodes A, Alhazzani W, Antonelli M, Cooper-Smith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* 2021;47:1181–247. doi:10.1007/s00134-021-06506-y.
- [52] Evans SR, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, et al. Rapid molecular diagnostics, antibiotic treatment decisions, and developing approaches to inform empiric therapy: PRIMERS I and II. *Clin Infect Dis* 2016;62:181–9. doi:10.1093/cid/civ837.
- [53] Evans SR, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, et al., Correction for Evans Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against *Acinetobacter* spp. in PRIMERS III. *J Clin Microbiol* 2017;55:1970. doi:10.1128/JCM.00525-17.
- [54] Zhi M, Ding EL, Theisen-Toupal J, Whelan J, Arnaout R. The landscape of inappropriate laboratory testing: a 15-year meta-analysis. *PLoS One* 2013;8:e78962. doi:10.1371/journal.pone.0078962.
- [55] Clinical Laboratory Tests: Which, Why, and What Do The Results Mean? | Laboratory Medicine | Oxford Academic n.d. <https://academic.oup.com/labmed/article/40/2/105/2504825> (accessed December 14, 2022).
- [56] Pollock NR. Ultrasensitive detection and quantification of toxins for optimized diagnosis of *Clostridium difficile* infection. *J Clin Microbiol* 2016;54:259–64. doi:10.1128/JCM.02419-15.
- [57] Senchyna F, Gaur RL, Gombas S, Truong CY, Schroeder LF, Banaei N. *Clostridium difficile* PCR Cycle Threshold Predicts Free Toxin. *J Clin Microbiol* 2017;55:2651–60. doi:10.1128/JCM.00563-17.
- [58] Kaleta EJ, Clark AE, Johnson DR, Gamage DC, Wysocki VH, Cherkauoi A, et al. Use of PCR coupled with electrospray ionization mass spectrometry for rapid identification of bacterial and yeast bloodstream pathogens from blood culture bottles. *J Clin Microbiol* 2011;49:345–53. doi:10.1128/JCM.00936-10.
- [59] Flurin L, Wolf MJ, Fisher CR, Cano Cevallos EJ, Vaillant JJ, Pritt BS, et al. Pathogen detection in infective endocarditis using targeted metagenomics on whole blood and plasma: a prospective pilot study. *J Clin Microbiol* 2022;60(9):e0062122. doi:10.1128/jcm.00621-22.
- [60] Huang AM, Newton D, Kunapuli A, Gandhi TN, Washer LL, Isip J, et al. Impact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia. *Clin Infect Dis* 2013;57:1237–45. doi:10.1093/cid/cit498.
- [61] Bauer KA, West JE, Balada-Llasat J-M, Pancholi P, Stevenson KB, Goff DA. An antimicrobial stewardship program's impact with rapid polymerase chain reaction methicillin-resistant *Staphylococcus aureus*/S. aureus blood culture test in patients with S. aureus bacteremia. *Clin Infect Dis* 2010;51:1074–80. doi:10.1086/656623.
- [62] Bauer KA, Perez KK, Forrest GN, Goff DA. Review of rapid diagnostic tests used by antimicrobial stewardship programs. *Clin Infect Dis* 2014;59(Suppl 3):S134–45. doi:10.1093/cid/ciu547.
- [63] Swoboda SM, Dixon T, Lipsitt PA. Can the clinical pulmonary infection score impact ICU antibiotic days? *Surg Infect (Larchmt)* 2006;7:331–9. doi:10.1089/sur.2006.7.331.
- [64] Nussenblatt V, Avdic E, Berenholtz S, Daugherty E, Hadhazy E, Lipsitt PA, et al. Ventilator-associated pneumonia: overdiagnosis and treatment are common in medical and surgical intensive care units. *Infect Control Hosp Epidemiol* 2014;35:278–84. doi:10.1086/675279.
- [65] Morgan DJ, Malani P, Diekema DJ. Diagnostic stewardship-leveraging the laboratory to improve antimicrobial use. *JAMA* 2017;318:607–8. doi:10.1001/jama.2017.8531.
- [66] Bates DW, Cook EF, Goldman L, Lee TH. Predicting bacteremia in hospitalized patients. A prospectively validated model. *Ann Intern Med* 1990;113:495–500. doi:10.7326/0003-4819-113-7-495.
- [67] Dargère S, Parienti J-J, Roupie E, Gancel P-E, Wiel E, Smaiti N, et al. Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study. *Clin Microbiol Infect* 2014;20:O920–7. doi:10.1111/1469-0691.12656.
- [68] Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? *JAMA* 2012;308:502–11. doi:10.1001/jama.2012.8262.
- [69] Linsenmeyer K, Gupta K, Strymish JM, Dhanani M, Brecher SM, Breu AC. Culture if spikes? Indications and yield of blood cultures in hospitalized medical patients. *J Hosp Med* 2016;11:336–40. doi:10.1002/jhm.2541.
- [70] Zalmanovici Trestioreanu A, Lador A, Sauerbrun-Cutler M-T, Leibovici L. Antibiotics for asymptomatic bacteriuria. *Cochrane Database Syst Rev* 2015;4:CD009534. doi:10.1002/14651858.CD009534.pub2.
- [71] Hansson S, Jodal U, Lincoln K, Svanborg-Edén C. Untreated asymptomatic bacteriuria in girls: II—Effect of phenoxymethylpenicillin and erythromycin given for intercurrent infections. *BMJ* 1989;298:856–9. doi:10.1136/bmj.298.6677.856.
- [72] Harding GKM, Zhanel GG, Nicolle LE, Cheang M, Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. *N Engl J Med* 2002;347:1576–83. doi:10.1056/NEJMoa021042.
- [73] Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2019;68:1611–15. doi:10.1093/cid/ciz021.
- [74] Leman P. Validity of urinalysis and microscopy for detecting urinary tract infection in the emergency department. *Eur J Emerg Med* 2002;9:141–7. doi:10.1097/00063110-200206000-00008.
- [75] Tansarli GS, Chapin KC. Diagnostic test accuracy of the BioFire® FilmArray® meningitis/encephalitis panel: a systematic review and meta-analysis. *Clin Microbiol Infect* 2020;26:281–90. doi:10.1016/j.cmi.2019.11.016.
- [76] Kim KS. Acute bacterial meningitis in infants and children. *Lancet Infect Dis* 2010;10:32–42. doi:10.1016/S1473-3099(09)70306-8.
- [77] Acuña M, Benadof D, Yohannessen K, Leiva Y, Clement P. FilmArray® Meningoencephalitis panel in the diagnosis of central nervous system infections: stewardship and cost analysis in a paediatric hospital in Chile. *BMC Pediatr* 2022;22:182. doi:10.1186/s12887-022-03241-1.
- [78] Moffa MA, Bremmer DN, Carr D, Buchanan C, Shively NR, Elrufay R, et al. Impact of a multiplex polymerase chain reaction assay on the clinical management of adults undergoing a lumbar puncture for suspected community-onset central nervous system infections. *Antibiotics (Basel)* 2020;9:282. doi:10.3390/antibiotics9060282.
- [79] McGlynn EA, McDonald KM, Cassel CK. Measurement Is essential for improving diagnosis and reducing diagnostic error: A Report From the Institute of Medicine. *JAMA* 2015;314:2501–2. doi:10.1001/jama.2015.13453.
- [80] Goodlet KJ, Tan E, Knutson L, Nailor MD. Impact of the FilmArray meningitis/encephalitis panel on antimicrobial duration among patients with suspected central nervous system infection. *Diagn Microbiol Infect Dis* 2021;100:115394. doi:10.1016/j.diagmicrobio.2021.115394.
- [81] Patel R, Fang FC. Diagnostic stewardship: Opportunity for a laboratory-infectious diseases partnership. *Clin Infect Dis* 2018;67(5):799–801. doi:10.1093/cid/ciy077.
- [82] Gaensbauer JT, Birkholz M, Pfannenstern K, Todd JK. Herpes PCR testing and empiric acyclovir use beyond the neonatal period. *Pediatrics* 2014;134:e651–6. doi:10.1542/peds.2014-0294.
- [83] Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of *Clostridium difficile* infection. *Infect Control Hosp Epidemiol* 2009;30:57–66. doi:10.1086/592981.
- [84] Lee HS, Plechot K, Gohil S, Le J. Diagnosis and the consequence of over diagnosis. *Infect Dis Ther* 2021;10(2):687–97. doi:10.1007/s40121-021-00417-7.
- [85] Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, et al. Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med* 2015;175:1792–801. doi:10.1001/jamainternmed.2015.4114.
- [86] Buckel WR, Avdic E, Carroll KC, Gunaseelan V, Hadhazy E, Cosgrove SE. Gut check: *Clostridium difficile* testing and treatment in the molecular testing era. *Infect Control Hosp Epidemiol* 2015;36:217–21. doi:10.1017/ice.2014.19.
- [87] Madden GR, Weinstein RA, Sifri CD. Diagnostic stewardship for healthcare-associated infections: opportunities and challenges to safely reduce test use. *Infect Control Hosp Epidemiol* 2018;39:214–18. doi:10.1017/ice.2017.278.
- [88] Cançado GGL, de Abreu ES, Nardelli MJ, Serwa P, Brachmann M. A cost of illness comparison for toxigenic *Clostridioides difficile* diagnosis algorithms in developing countries. *Anaerobe* 2021;70:102390. doi:10.1016/j.anaerobe.2021.102390.
- [89] Lamendella R, Wright JR, Hackman J, McLimans C, Toole DR, Bernard Rubio W, et al. Antibiotic treatments for *Clostridium difficile* infection are associated with distinct bacterial and fungal community structures. *MSphere* 2018;3:e00572-17. doi:10.1128/mSphere.00572-17.
- [90] Cannon K, Byrne B, Happe J, Wu K, Ward L, Chesnel L, et al. Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin ver-



- sus vancomycin for the treatment of *Clostridium difficile* infection. *J Antimicrob Chemother* 2017;72:3453–61. doi:10.1093/jac/dkx318.
- [91] Bartsch SM, Umscheid CA, Nachamkin I, Hamilton K, Lee BY. Comparing the economic and health benefits of different approaches to diagnosing *Clostridium difficile* infection. *Clin Microbiol Infect* 2015;21:77.e1–9. doi:10.1016/j.cmi.2014.07.002.
- [92] Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2016;22(Suppl 4):S63–81. doi:10.1016/j.cmi.2016.03.010.
- [93] Leffler DA, Lamont JT. *Clostridium difficile* infection. *N Engl J Med* 2015;372:1539–48. doi:10.1056/NEJMr1403772.
- [94] Curtin BF, Zarbalian Y, Flasar MH, von Rosenvinge E. *Clostridium difficile*-associated disease: Adherence with current guidelines at a tertiary medical center. *World J Gastroenterol* 2013;19:8647–51. doi:10.3748/wjg.v19.i46.8647.
- [95] McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66:e1–48. doi:10.1093/cid/cix1085.
- [96] Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;31:431–55. doi:10.1086/651706.
- [97] Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C. difficile* infection. *Lancet Infect Dis* 2013;13:936–45. doi:10.1016/S1473-3099(13)70200-7.
- [98] Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. *Radiology* 2020;296:E115–17. doi:10.1148/radiol.2020200432.
- [99] Guh AY, Hatfield KM, Winston LG, Martin B, Johnston H, Brousseau G, et al. Toxin enzyme immunoassays detect *Clostridioides difficile* infection with greater severity and higher recurrence rates. *Clin Infect Dis* 2019;69:1667–74. doi:10.1093/cid/ciz009.
- [100] Ramos CP, Lopes EO, Diniz AN, Lobato FCF, Vilela EG, Silva ROS. Evaluation of glutamate dehydrogenase (GDH) and toxin A/B rapid tests for *Clostridioides* (prev. *Clostridium*) *difficile* diagnosis in a university hospital in Minas Gerais, Brazil. *Braz J Microbiol* 2020;51:1139–43. doi:10.1007/s42770-020-00288-z.
- [101] Mermel LA, Jefferson J, Blanchard K, Parenteau S, Mathis B, Chapin K, et al. Reducing *Clostridium difficile* incidence, colectomies, and mortality in the hospital setting: a successful multidisciplinary approach. *Jt Comm J Qual Patient Saf* 2013;39:298–305. doi:10.1016/s1553-7250(13)39042-4.
- [102] Hecker MT, Son AH, Alhmid H, Wilson BM, Wiest PM, Donskey CJ. Efficacy of a stewardship intervention focused on reducing unnecessary use of non-*Clostridioides difficile* antibiotics in patients with *Clostridioides difficile* infection. *Infect Control Hosp Epidemiol* 2020;41:216–18. doi:10.1017/ice.2019.346.
- [103] Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society n.d. [https://www.idsociety.org/practice-guideline/hap\\_vap/](https://www.idsociety.org/practice-guideline/hap_vap/) (accessed December 14, 2022).
- [104] Hellyer TP, McAuley DF, Walsh TS, Anderson N, Conway Morris A, Singh S, et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. *Lancet Respir Med* 2020;8:182–91. doi:10.1016/S2213-2600(19)30367-4.
- [105] Berton DC, Kalil AC, Teixeira PJZ. Quantitative versus qualitative cultures of respiratory secretions for clinical outcomes in patients with ventilator-associated pneumonia. *Cochrane Database Syst Rev* 2014;CD006482. doi:10.1002/14651858.CD006482.pub4.
- [106] Musgrove MA, Kenney RM, Kendall RE, Peters M, Tibbetts R, Samuel L, et al. Microbiology comment nudge improves pneumonia prescribing. *Open Forum Infect Dis* 2018;5(7):ofy162. doi:10.1093/ofid/ofy162.
- [107] Yoshimura J, Yamakawa K, Ohta Y, Nakamura K, Hashimoto H, Kawada M, et al. Effect of Gram stain-guided initial antibiotic therapy on clinical response in patients with ventilator-associated pneumonia: The GRACE-VAP randomized clinical trial. *JAMA Netw Open* 2022;5:e226136. doi:10.1001/jamanetworkopen.2022.6136.
- [108] Copeland-Halperin LR, Emery E, Collins D, Liu C, Dort J. Dogma without Data: A Clinical Decision-Making Tool for Postoperative Blood Cultures. *Am Surg* 2018;84(8):1339–44 PMID: 30185313.
- [109] Fabre V, Klein E, Salinas AB, Jones G, Carroll KC, Milstone AM, et al. A diagnostic stewardship intervention to improve blood culture use among adult nonneutropenic inpatients: the DISTRIBUTE Study. *J Clin Microbiol* 2020;58:e01053–20. doi:10.1128/JCM.01053-20.
- [110] Scheer CS, Fuchs C, Gründling M, Vollmer M, Bast J, Bohnert JA, et al. Impact of antibiotic administration on blood culture positivity at the beginning of sepsis: a prospective clinical cohort study. *Clin Microbiol Infect* 2019;25:326–31. doi:10.1016/j.cmi.2018.05.016.
- [111] Lee ALH, Leung ECM, Lee MKP, Lai RWM. Diagnostic stewardship programme for urine culture: impact on antimicrobial prescription in a multi-centre cohort. *J Hosp Infect* 2021;108:81–9. doi:10.1016/j.jhin.2020.10.027.
- [112] Epstein L, Edwards JR, Halpin AL, Preas MA, Blythe D, Harris AD, et al. Evaluation of a novel intervention to reduce unnecessary urine cultures in intensive care units at a tertiary care hospital in Maryland, 2011–2014. *Infect Control Hosp Epidemiol* 2016;37:606–9. doi:10.1017/ice.2016.9.
- [113] Broadhurst MJ, Dujari S, Budvytiene I, Pinsky BA, Gold CA, Banaei N. Utilization, yield, and accuracy of the FilmArray meningitis/encephalitis panel with diagnostic stewardship and testing algorithm. *J Clin Microbiol* 2020;58:e00311–20. doi:10.1128/JCM.00311-20.
- [114] Quan KA, Yim J, Merrill D, Khusbu U, Madey K, Dickey L, et al. Reductions in *Clostridium difficile* Infection (CDI) rates using real-time automated clinical criteria verification to enforce appropriate testing. *Infect Control Hosp Epidemiol* 2018;39:625–7. doi:10.1017/ice.2018.32.
- [115] Christensen AB, Barr VO, Martin DW, Anderson MM, Gibson AK, Hoff BM, et al. Diagnostic stewardship of *C. difficile* testing: a quasi-experimental antimicrobial stewardship study. *Infect Control Hosp Epidemiol* 2019;40:269–75. doi:10.1017/ice.2018.336.
- [116] Brecher SM, Novak-Weekley SM, Nagy E. Laboratory diagnosis of *Clostridium difficile* infections: there is light at the end of the colon. *Clin Infect Dis* 2013;57:1175–81. doi:10.1093/cid/cit424.
- [117] Truong CY, Gombar S, Wilson R, Sundararajan G, Tekic N, Holubar M, et al. Real-time electronic tracking of diarrheal episodes and laxative therapy enables verification of *Clostridium difficile* clinical testing criteria and reduction of *Clostridium difficile* infection rates. *J Clin Microbiol* 2017;55:1276–84. doi:10.1128/JCM.02319-16.
- [118] Pierce J, Apisarnthanarak A, Schellack N, Cornistein W, Maani AA, Adnan S, et al. Global antimicrobial stewardship with a focus on low- and middle-income countries: A position statement for the international society for infectious diseases. *Int J Infect Dis* 2020;96:621–9. doi:10.1016/j.ijid.2020.05.126.
- [119] Rizk NA, Moghnieh R, Haddad N, Rebeiz M-C, Zeenny RM, Hindy J-R, et al. Challenges to antimicrobial stewardship in the countries of the Arab League: Concerns of worsening resistance during the COVID-19 pandemic and proposed solutions. *Antibiotics (Basel)* 2021;10:1320. doi:10.3390/antibiotics10111320.
- [120] Wertheim HFL, Huong VTL, Kuijper EJ. Clinical microbiology laboratories in low-resource settings, it is not only about equipment and reagents, but also good governance for sustainability. *Clin Microbiol Infect* 2021;27:1389–90. doi:10.1016/j.cmi.2021.07.027.